The advent of highly specific inhibitors for oncogenic BRAF with robust activity in BRAFV600E mutant melanoma [3], [8], [9], [10] and the clinical development of specific inhibitors of PI3K, AKT and mTOR, provide the tools to translate these concepts into the clinic. The gene discussed is MTOR; the disease is melanoma.